MCID: ACT098
MIFTS: 48

Acute Erythroid Leukemia

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Acute Erythroid Leukemia

MalaCards integrated aliases for Acute Erythroid Leukemia:

Name: Acute Erythroid Leukemia 38 53
Acute Myeloid Leukemia, M6 Type 29 6
Acute Myeloid Leukemia Fab-M6 53 73
Acute Erythroleukemia 53 73
Erythroleukemia 53 55
Acute Erythroleukemia - M6a Subtype 73
Acute Erythroleukemia - M6b Subtype 73
Acute Erythroleukemia M6a Subtype 53
Acute Erythroleukemia M6b Subtype 53
Acute Erythroblastic Leukemia 73
Acute Myeloid Leukemia M6 53
Di Guglielmo's Syndrome 53
Di Guglielmo Syndrome 53
Aml M6 53
Aml-M6 53

Classifications:



Summaries for Acute Erythroid Leukemia

MalaCards based summary : Acute Erythroid Leukemia, also known as acute myeloid leukemia, m6 type, is related to leukemia and megakaryocytic leukemia. An important gene associated with Acute Erythroid Leukemia is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Mesna and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are liver/biliary system and normal

Wikipedia : 76 Acute erythroid leukemia or Di Guglielmo syndrome is a rare form of acute myeloid leukemia (less than 5%... more...

Related Diseases for Acute Erythroid Leukemia

Diseases related to Acute Erythroid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.7 CEBPA JAK2 TP53
2 megakaryocytic leukemia 29.8 JAK2 TP53
3 myelodysplastic syndrome 29.3 CEBPA GATA2 JAK2 TP53
4 myeloid leukemia 28.9 CEBPA GATA2 JAK2 PICALM TP53
5 erythroleukemia, familial 11.3
6 anemia, congenital dyserythropoietic, type iii 11.3
7 folate malabsorption, hereditary 11.1
8 pernicious anemia 10.3
9 sarcoma 10.1
10 teratocarcinoma 10.1
11 embryonal carcinoma 10.1
12 hypoxia 10.1
13 macrocytic anemia 10.0
14 paroxysmal nocturnal hemoglobinuria 10.0
15 thalassemia 10.0
16 hemoglobinuria 10.0
17 core binding factor acute myeloid leukemia 10.0 CEBPA JAK2
18 thyroid lymphoma 9.9 PICALM TP53
19 leukemia, chronic lymphocytic 2 9.9
20 leukemia, chronic lymphocytic 9.9
21 myeloma, multiple 9.9
22 acute leukemia 9.9
23 lymphocytic leukemia 9.9
24 vasculitis 9.9
25 leukemia, b-cell, chronic 9.9
26 myelodysplastic syndrome with excess blasts 9.9
27 myelofibrosis 9.9
28 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.9
29 congenital dyserythropoietic anemia 9.9
30 hypersensitivity reaction type iv disease 9.9
31 plasmacytoma 9.9
32 acquired idiopathic sideroblastic anemia 9.9
33 refractory anemia 9.9
34 fetal hemoglobin quantitative trait locus 1 9.8
35 pelger-huet anomaly 9.8
36 retinoblastoma 9.8
37 neuroblastoma 9.8
38 pyruvate kinase deficiency of red cells 9.8
39 reticulum cell sarcoma 9.8
40 werner syndrome 9.8
41 alpha-thalassemia myelodysplasia syndrome 9.8
42 alpha-thalassemia 9.8
43 ovarian cancer 1 9.8
44 leukemia, chronic myeloid 9.8
45 hemoglobin h disease 9.8
46 beta-thalassemia 9.8
47 leukotriene c4 synthase deficiency 9.8
48 sclerosing cholangitis, neonatal 9.8
49 hemophagocytic lymphohistiocytosis 9.8
50 lymphoma 9.8

Graphical network of the top 20 diseases related to Acute Erythroid Leukemia:



Diseases related to Acute Erythroid Leukemia

Symptoms & Phenotypes for Acute Erythroid Leukemia

MGI Mouse Phenotypes related to Acute Erythroid Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.35 CEBPA GATA2 JAK2 PICALM TP53
2 normal MP:0002873 9.02 CEBPA FHL2 GATA2 JAK2 TP53

Drugs & Therapeutics for Acute Erythroid Leukemia

Drugs for Acute Erythroid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
4
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
7
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
9
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
10
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
11
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
12
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
13
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
14
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
15
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
16
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
18
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
20
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
21
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
22
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
23
Prednisone Approved, Vet_approved Phase 3,Phase 1 53-03-2 5865
24
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
25
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
26
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
27
Carmustine Approved, Investigational Phase 3 154-93-8 2578
28
Hydroxyurea Approved Phase 3 127-07-1 3657
29
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
30
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
31
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
32
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
33
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
34
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
35
Midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
38
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
40
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
41 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Etoposide phosphate Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
2 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
3 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
4 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
9 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
10 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
11 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
14 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
15 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
16 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
17 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
18 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
19 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
24 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
25 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
26 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
27 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
28 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
29 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
30 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
31 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
34 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
37 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Unknown status NCT00509093 Phase 2 imatinib mesylate
38 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
39 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
40 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
41 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
42 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
43 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
44 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2 vorinostat;vorinostat
45 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
46 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
47 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
48 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
49 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
50 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine

Search NIH Clinical Center for Acute Erythroid Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Erythroid Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Erythroid Leukemia

Genetic tests related to Acute Erythroid Leukemia:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia, M6 Type 29

Anatomical Context for Acute Erythroid Leukemia

MalaCards organs/tissues related to Acute Erythroid Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Brain, Thyroid, B Cells

Publications for Acute Erythroid Leukemia

Articles related to Acute Erythroid Leukemia:

(show all 36)
# Title Authors Year
1
The anticancer effects of pharmacological inhibition of autophagy in acute erythroid leukemia cells. ( 29994802 )
2018
2
Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. ( 28841205 )
2017
3
An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. ( 28793875 )
2017
4
Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. ( 28886412 )
2017
5
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. ( 27443511 )
2016
6
The disappearance of acute erythroid leukemia: An act of legerdemain at the World Health Organization. ( 27667167 )
2016
7
microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. ( 27086927 )
2016
8
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. ( 27244257 )
2016
9
Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia. ( 27389056 )
2016
10
Extreme dyserythropoiesis in the setting of acute erythroid leukemia. ( 26605391 )
2015
11
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. ( 26202927 )
2015
12
Differential diagnoses of macrocytic anemia, reticulocytosis and low serum haptoglobin in patients with myelodysplastic syndromes/acute leukemia: comment on "two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis". ( 24390535 )
2014
13
Acute erythroid leukemia in a patient with chronic lymphocytic leukemia. ( 25536628 )
2014
14
Large vessel vasculitis developed early after allogeneic bone marrow transplant for acute erythroid leukemia. ( 23517561 )
2013
15
Two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis. ( 23812200 )
2013
16
Fusion of ZMYND8 and RELA genes in acute erythroid leukemia. ( 23667654 )
2013
17
Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. ( 23871646 )
2013
18
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. ( 23648669 )
2013
19
High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). ( 23032695 )
2013
20
Erythropoietin-induced acute erythroid leukemia-like picture: A potential pitfall. ( 24239851 )
2013
21
Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. ( 21780998 )
2012
22
Block of red blood cell maturation in acute erythroid leukemia. ( 23115799 )
2012
23
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. ( 21996560 )
2012
24
S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13). ( 22147971 )
2011
25
FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. ( 22829078 )
2011
26
Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. ( 21264917 )
2011
27
Acute erythroid leukemia with multilineage dysplasia in a cat. ( 21731091 )
2011
28
Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia. ( 21606959 )
2011
29
Acute erythroid leukemia. ( 20807044 )
2010
30
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. ( 20040759 )
2010
31
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. ( 20473273 )
2010
32
Acute erythroid leukemia (AML-M6) - Is it rare? ( 27265109 )
2009
33
Recommendation of the use of myeloblast percentage among non-erythroid cells instead of percentage among total nucleated cells for therapeutic response assessment in acute erythroid leukemia. ( 16690527 )
2006
34
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. ( 16034466 )
2005
35
Acute erythroid leukemia (M6): outcome of bone marrow transplantation. ( 10512167 )
1999
36
Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases. ( 1068531 )
1976

Variations for Acute Erythroid Leukemia

ClinVar genetic disease variations for Acute Erythroid Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EPOR NM_000121.3(EPOR): c.1460A> G (p.Asn487Ser) single nucleotide variant Likely benign rs62638745 GRCh37 Chromosome 19, 11488727: 11488727
2 EPOR NM_000121.3(EPOR): c.1460A> G (p.Asn487Ser) single nucleotide variant Likely benign rs62638745 GRCh38 Chromosome 19, 11378051: 11378051
3 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh38 Chromosome 12, 56102035: 56102035
4 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh37 Chromosome 12, 56495819: 56495819

Expression for Acute Erythroid Leukemia

Search GEO for disease gene expression data for Acute Erythroid Leukemia.

Pathways for Acute Erythroid Leukemia

GO Terms for Acute Erythroid Leukemia

Biological processes related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.58 CEBPA JAK2 TP53
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.56 CEBPA FHL2 GATA2 TP53
3 cytokine-mediated signaling pathway GO:0019221 9.54 CEBPA JAK2 TP53
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.48 JAK2 TP53
5 positive regulation of inflammatory response GO:0050729 9.46 CEBPA JAK2
6 hemopoiesis GO:0030097 9.43 GATA2 PICALM
7 cell maturation GO:0048469 9.32 CEBPA GATA2
8 response to antibiotic GO:0046677 9.16 JAK2 TP53
9 embryonic placenta development GO:0001892 8.96 CEBPA GATA2
10 positive regulation of transcription, DNA-templated GO:0045893 8.92 CEBPA FHL2 PICALM TP53

Molecular functions related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.33 CEBPA GATA2 TP53
2 identical protein binding GO:0042802 9.26 FHL2 JAK2 PCM1 TP53
3 transcription factor binding GO:0008134 8.92 CEBPA FHL2 GATA2 TP53

Sources for Acute Erythroid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....